[Federal Register Volume 83, Number 207 (Thursday, October 25, 2018)]
[Notices]
[Pages 53928-53934]
[FR Doc No: 2018-23278]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-84456; File No. SR-CboeBZX-2018-078]

Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of
Filing of a Proposed Rule Change To List and Trade Shares of the
WisdomTree Long-Term Treasury PutWrite Strategy Fund, WisdomTree
Corporate Bond PutWrite Strategy Fund, WisdomTree International
PutWrite Strategy Fund, and WisdomTree Emerging Markets PutWrite
Strategy Fund, Each a Series of WisdomTree Trust, Under Rule 14.11(i),
Managed Fund Shares

October 19, 2018.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(the ``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given
that on October 9, 2018, Cboe BZX Exchange, Inc. (the ``Exchange'' or
``BZX'') filed with the Securities and Exchange Commission
(``Commission'') the proposed rule change as described in Items I, II,
and III below, which Items have been prepared by the Exchange. The
Commission is publishing this notice to solicit comments on the
proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange filed a proposal to list and trade shares of the
WisdomTree Long-Term Treasury PutWrite Strategy Fund, WisdomTree
Corporate Bond PutWrite Strategy Fund, WisdomTree International
PutWrite Strategy Fund, and WisdomTree Emerging Markets PutWrite
Strategy Fund, each a series of the WisdomTree Trust (the ``Trust''),
under Rule 14.11(i) (``Managed Fund Shares'').
    The text of the proposed rule change is available at the Exchange's
website at www.markets.cboe.com, at the principal office of the
Exchange, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant parts of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange proposes to list and trade shares (``Shares'') of the
WisdomTree Long-Term Treasury PutWrite Strategy Fund, WisdomTree
Corporate Bond PutWrite Strategy Fund, WisdomTree International
PutWrite Strategy Fund, and WisdomTree Emerging Markets PutWrite
Strategy Fund (each a ``Fund'' and, collectively, the ``Funds'') under
Rule 14.11(i), which governs the listing and trading of Managed Fund
Shares on the Exchange.
    The Shares will be offered by the WisdomTree Trust, which was
established as a Delaware statutory trust on December 15, 2005. The
Trust is registered with the Commission as an investment company and
has filed a registration statement on Form N-1A (``Registration
Statement'') with the Commission on behalf of the Funds.\3\
---------------------------------------------------------------------------

    \3\ See Post-Effective Amendment Nos. 641-644 to the
Registration Statement on Form N-1A for the Trust, dated September
19, 2018 (File Nos. 333-132380 and 811-21864). The descriptions of
the Funds and the Shares contained herein are based on information
in the Registration Statement.
---------------------------------------------------------------------------

    Exchange Rule 14.11(i)(7) provides that, if the investment adviser
to the investment company issuing Managed Fund Shares is affiliated
with a broker-dealer, such investment adviser shall erect and maintain
a ``fire wall'' between the investment adviser and the broker-dealer
with respect to access to information concerning the composition and/or
changes to such investment company portfolio.\4\ In addition, Exchange
Rule 14.11(i)(7) further requires that personnel who make decisions on
the investment company's portfolio composition must be subject to
procedures designed to prevent the use and dissemination of material
nonpublic information regarding the applicable investment company
portfolio. Exchange Rule 14.11(i)(7) is similar to Exchange Rule
14.11(b)(5)(A)(i) (which applies to index-based funds); however,
Exchange Rule 14.11(i)(7) in connection with the establishment of a
``fire wall'' between the investment adviser and the broker-dealer
reflects the applicable open-end fund's portfolio, not an underlying
benchmark index, as is the case with index-based funds. The Adviser is
not a registered broker-dealer and is not affiliated with any broker-
dealers that are in the business of buying or selling securities. The
Sub-Adviser is affiliated with multiple broker-dealers and has
implemented a ``fire wall'' with respect to such broker-dealers and
their personnel regarding access to information regarding access to
information [sic] concerning the composition and/or changes to a Fund's
portfolio. In addition, Sub-Adviser personnel who make decisions
regarding a Fund's portfolio are subject to procedures designed to
prevent the use and dissemination of material nonpublic information
regarding such Fund's portfolio. In the event that (a) the Adviser or
Sub-Adviser becomes registered as a broker-dealer or newly affiliated
with a broker-dealer, or (b) any new adviser or sub-adviser is a
registered broker-dealer or becomes affiliated with a broker-dealer, it
will implement and maintain a fire wall with respect to its relevant
personnel or such broker-dealer affiliate, as applicable, regarding
access to information concerning the composition and/or changes to the
portfolio, and will be subject to procedures designed to prevent the
use and dissemination of material non-public information regarding such
portfolio.
---------------------------------------------------------------------------

    \4\ An investment adviser to an open-end fund is required to be
registered under the Investment Advisers Act of 1940 (the ``Advisers
Act''). As a result, the Adviser and its related personnel are
subject to the provisions of Rule 204A-1 under the Advisers Act
relating to codes of ethics. This Rule requires investment advisers
to adopt a code of ethics that reflects the fiduciary nature of the
relationship to clients as well as compliance with other applicable
securities laws. Accordingly, procedures designed to prevent the
communication and misuse of non-public information by an investment
adviser must be consistent with Rule 204A-1 under the Advisers Act.
In addition, Rule 206(4)-7 under the Advisers Act makes it unlawful
for an investment adviser to provide investment advice to clients
unless such investment adviser has (i) adopted and implemented
written policies and procedures reasonably designed to prevent
violation, by the investment adviser and its supervised persons, of
the Advisers Act and the Commission rules adopted thereunder; (ii)
implemented, at a minimum, an annual review regarding the adequacy
of the policies and procedures established pursuant to subparagraph
(i) above and the effectiveness of their implementation; and (iii)
designated an individual (who is a supervised person) responsible
for administering the policies and procedures adopted under
subparagraph (i) above.
---------------------------------------------------------------------------

    Each Fund intends to qualify each year as a regulated investment
company under Subchapter M of the Internal Revenue Code of 1986, as
amended.
    The Exchange submits this proposal in order to allow each Fund to
hold listed derivatives (i.e., Puts, as defined below) in a manner that
does not comply with Exchange Rule 14.11(i)(4)(C)(iv)(b).\5\
Specifically, each Fund seeks to achieve its respective investment
objective primarily through a strategy of selling listed put options on
exchange traded funds (``ETFs'') \6\ in a manner that does not meet the
requirements of Rule 14.11(i)(4)(C)(iv)(b), while investing the sales
proceeds in Treasury Bills. The Funds may also hold a very limited
amount of certain fixed income securities and mutual funds that do not
comply with the holdings requirements in Rule 14.11(i)(4)(C)(ii) and
14.11(i)(4)(C)(i), respectively, as further described below. Otherwise,
each Fund will comply with all other listing requirements on an initial
and continued listing basis under Exchange Rule 14.11(i) for Managed
Fund Shares. The Exchange notes that the Commission has previously
approved the listing and trading of two funds that employ very similar
indexed strategies.\7\
---------------------------------------------------------------------------

    \5\ Exchange Rule 14.11(i)(4)(C)(iv)(b) provides that ``the
aggregate gross notional value of listed derivatives based on any
five or fewer underlying reference assets shall not exceed 65% of
the weight of the portfolio (including gross notional exposures),
and the aggregate gross notional value of listed derivatives based
on any single underlying reference asset shall not exceed 30% of the
weight of the portfolio (including gross notional exposures).''
    \6\ For purposes of this filing the term ETF shall mean
Portfolio Depository Receipts as defined in Rule 14.11(b), Index
Fund Shares as defined in Rule 14.11(c), and Managed Fund Shares as
defined in Rule 14.11(i), or the equivalent product type on other
national securities exchanges. With respect to Index Fund Shares,
the underlying index shall be referred to herein as an ``Index.''
    \7\ See Securities Exchange Act Release Nos. 81876 (October 16,
2017), 82 FR 48861 (October 20, 2017) (order approving proposed rule
change to list shares of the WisdomTree CBOE Russell 2000 PutWrite
Strategy Fund); 74675 (April 8, 2015), 80 FR 20038 (April 14, 2015)
(order approving proposed rule change to list shares of the Wisdom
Tree Put Write Strategy Fund); and 77045 (February 3, 2016), 81 FR
6916 (February 9, 2016) (order approving a proposed rule change
relating to the index underlying the WisdomTree Put Write Strategy
Fund). If such funds were evaluated under the generic listing
standards for Managed Fund Shares applicable under Rule 14.11(i),
they would not meet the generic listing standards in the same way as
the Funds would not meet the generic listing standards.
---------------------------------------------------------------------------

PutWrite Strategy
    In a put writing strategy, a Fund (as the seller of the option)
receives premiums from the purchaser of the

option in exchange for providing the purchaser with the right to sell
the underlying instrument to the Fund at a specific price (i.e., the
exercise price or strike price). If the market price of the instrument
underlying the option exceeds the strike price, it is anticipated that
the option would go unexercised and the Fund would earn the full
premium upon the option's expiration or a portion of the premium upon
the option's early termination. If the market price of the instrument
underlying the option drops below the strike price, it is anticipated
that the option would be exercised and the Fund would pay the option
buyer the difference between the market value of the underlying
instrument and the strike price. The proceeds received by a Fund for
writing put options will generally be invested in Treasury Bills in
order to seek to offset any liabilities the Fund incurs from writing
put options.
    The Sub-Adviser will select option investments based on estimates
of current and future market volatility levels, underlying instrument
valuations and perceived market risks and will evaluate relative option
premiums in determining preferred option contract terms, such as
exercise prices and expiration dates. At the time of writing (selling)
a put option, the aggregate investment exposure, as measured on a
notional basis (i.e., the value of the underlying instrument at its
strike price), of the options written by the Fund will not exceed 100%
of the Fund's total assets.
    Each Fund's investments will substantially consist of written put
options on one or more ETFs and Cash Equivalents.\8\
---------------------------------------------------------------------------

    \8\ As defined in Exchange Rule 14.11(i)(4)(C)(iii)(b), Cash
Equivalents include short-term instruments with maturities of less
than three months are: (i) U.S. Government securities, including
bills, notes, and bonds differing as to maturity and rates of
interest, which are either issued or guaranteed by the U.S. Treasury
or by U.S. Government agencies or instrumentalities; (ii)
certificates of deposit issued against funds deposited in a bank or
savings and loan association; (iii) bankers acceptances, which are
short-term credit instruments used to finance commercial
transactions; (iv) repurchase agreements and reverse repurchase
agreements; (v) bank time deposits, which are monies kept on deposit
with banks or savings and loan associations for a stated period of
time at a fixed rate of interest; (vi) commercial paper, which are
short-term unsecured promissory notes; and (vii) money market funds.
---------------------------------------------------------------------------

WisdomTree Long-Term Treasury PutWrite Strategy Fund
    The WisdomTree Long-Term Treasury PutWrite Strategy Fund seeks
long-term growth of capital and income generation. The Fund seeks to
achieve its investment objective primarily through a strategy of
writing listed put options on one or more ETFs that track the
performance of debt issued by the U.S. Treasury with remaining
maturities of 20 years or more.
WisdomTree High Yield Corporate Bond PutWrite Strategy Fund
    The WisdomTree High Yield Corporate Bond PutWrite Strategy Fund
seeks long-term growth of capital and income generation. The Fund seeks
to achieve its investment objective primarily through a strategy of
writing listed put options on one or more ETFs that track the
performance of U.S. high yield corporate debt.
WisdomTree International PutWrite Strategy Fund
    The WisdomTree International PutWrite Strategy Fund seeks long-term
growth of capital and income generation. The Fund seeks to achieve its
investment objective primarily through a strategy of writing listed put
options on one or more ETFs that track the equity market performance of
developed markets outside of the U.S. & Canada.
WisdomTree Emerging Markets PutWrite Strategy Fund
    The WisdomTree Emerging Markets PutWrite Strategy Fund seeks long-
term growth of capital and income generation. The Fund seeks to achieve
its investment objective primarily through a strategy of writing listed
put options on one or more ETFs that track the performance of large and
mid-cap emerging markets equities.
Investment Methodology
    Under Normal Market Conditions,\9\ each Fund will invest
substantially all of its assets in put options and one month or three-
month U.S. Treasury bills. Each Fund's investment strategy will be
designed to write a sequence of one-month, at-the-money, puts on the
applicable ETFs (the ``Puts'') \10\ and invest the proceeds from
writing such puts in Treasury bills. The number of Puts written will
vary from month to month, but will be limited to permit the amount held
in a Fund's investment in Treasury bills to finance the maximum
possible loss from final settlement of the Puts.
---------------------------------------------------------------------------

    \9\ The term ``Normal Market Conditions'' includes, but is not
limited to, the absence of trading halts in the applicable financial
markets generally; operational issues causing dissemination of
inaccurate market information or system failures; or force majeure
type events such as natural or man-made disaster, act of God, armed
conflict, act of terrorism, riot or labor disruption, or any similar
intervening circumstance. In response to adverse market, economic,
political, or other conditions, the Fund reserves the right to
invest in U.S. government securities, other money market instruments
(as defined below), and cash, without limitation, as determined by
the Adviser or Sub-Adviser. In the event the Fund engages in these
temporary defensive strategies that are inconsistent with its
investment strategies, the Fund's ability to achieve its investment
objectives may be limited.
    \10\ The term ``Puts'' will at any time include only puts on the
five ETFs that track the performance of the applicable market sector
that have the greatest total options consolidated average daily
exchange trading volume in such puts for the previous quarter. The
Fund will not invest in Puts on leveraged (e.g., 2X, -2X, 3X, or -
3X) ETFs.
---------------------------------------------------------------------------

    The new Puts will be struck and sold on a monthly basis, usually
the third Friday of the month (i.e., the ``Roll Date''), which matches
the expiration date of the current Puts. The strike price of the new
Puts will be based on the strike price of the put options with the
closest strike price below the last trade of the applicable ETF
reported before 11:00 a.m. ET. For example, if the last trade in the
applicable ETF reported before 11:00 a.m. ET is $50.23 and the closest
listed put option with a strike price below $50.23 is $50, then the $50
strike put option will be sold by the Fund.
Other Assets
    Each Fund may invest up to 20% of its net assets (in the aggregate)
in Other Assets. Other Assets includes only the following: Other ETF
put options; \11\ Index futures and/or options on Index futures; \12\
total return swaps; \13\ shares of other exchange traded products

(``ETPs''); \14\ shares of non-exchange-traded registered open-end
investment companies (i.e., mutual funds); \15\ and variable or
floating interest rate securities.\16\
---------------------------------------------------------------------------

    \11\ A Fund may invest up to 10% of its assets in over-the-
counter put options.
    \12\ A Fund will limit its direct investments in futures and
options on futures to the extent necessary for the Adviser to claim
the exclusion from regulation as a ``commodity pool operator'' with
respect to the Fund under Rule 4.5 promulgated by the Commodity
Futures Trading Commission (``CFTC''), as such rule may be amended
from time to time. Under Rule 4.5 as currently in effect, the Fund
would limit its trading activity in futures and options on futures
(excluding activity for ``bona fide hedging purposes,'' as defined
by the CFTC) such that it will meet one of the following tests: (i)
Aggregate initial margin and premiums required to establish its
futures and options on futures positions will not exceed 5% of the
liquidation value of the Fund's portfolio, after taking into account
unrealized profits and losses on such positions; or (ii) aggregate
net notional value of its futures and options on futures positions
will not exceed 100% of the liquidation value of the Fund's
portfolio, after taking into account unrealized profits and losses
on such positions.
     The exchange-listed futures contracts in which a Fund may
invest will be listed on exchanges in the U.S. Each of the exchange-
listed futures contracts in which the Fund may invest will be listed
on exchanges that are members of ISG.
    \13\ A Fund may use total return swaps to create positions
equivalent to investments in ETF put options and the component
securities underlying the applicable Index.
     A Fund's investments in total return swap agreements will be
backed by investments in U.S. government securities in an amount
equal to the exposure of such contracts.
    \14\ A Fund may invest in shares of both taxable and tax-
exempted money market funds. When used herein, ETPs may include,
without limitation, Index Fund Shares (as described in Rule
14.11(c)); Linked Securities (as described in Rule 14.11(d));
Portfolio Depositary Receipts (as described in Rule 14.11(b));
Trust-Issued Receipts (as described in Rule 14.11(f)); Commodity-
Based Trust Shares (as described in Rule 14.11(e)(4)); Currency
Trust Shares (as described in Rule 14.11(e)(5)); Commodity Index
Trust Shares (as described in Rule 14.11(e)(6)); Trust Units (as
described in Rule 14.11(e)(9)); Managed Fund Shares (as described in
Rule 14.11(i)), and closed-end funds. The ETPs in which the Fund may
invest all will be listed and traded on U.S. exchanges. The Fund may
invest in the securities of ETPs registered under the 1940 Act
consistent with the requirements of Section 12(d)(1) of the 1940 Act
or any rule, regulation or order of the Commission or interpretation
thereof. A Fund will only make such investments in conformity with
the requirements of Section 817 of the Internal Revenue Code of
1986. The ETPs in which the Fund may invest will primarily be index-
based ETFs that hold substantially all of their assets in securities
representing a specific index. The Fund will not invest in leveraged
(e.g., 2X, -2X, 3X, or -3X) ETPs.
    \15\ The Fund will not invest in leveraged (e.g., 2X, -2X, 3X,
or -3X) mutual funds.
    \16\ A Fund may invest in securities (in addition to U.S.
Treasury securities, described above) that have variable or floating
interest rates which are readjusted on set dates (such as the last
day of the month) in the case of variable rates or whenever a
specified interest rate change occurs in the case of a floating rate
instrument. Variable or floating interest rates generally reduce
changes in the market price of securities from their original
purchase price because, upon readjustment, such rates approximate
market rates. Accordingly, as interest rates decrease or increase,
the potential for capital appreciation or depreciation is less for
variable or floating rate securities than for fixed rate
obligations.
---------------------------------------------------------------------------

    As such, the Funds may hold certain fixed income securities and
mutual funds that do not comply with the holdings requirements in Rule
14.11(i)(4)(C)(ii) and 14.11(i)(4)(C)(i), respectively. The Exchange
does not believe that these holdings represent any substantive policy
concerns because they represent such a small portion of the portfolio.
In addition, the Funds additional holdings of ETPs and cash and cash
equivalents will meet the listing standards applicable in Rule
14.11(i)(4)(C)(i) and 14.11(i)(4)(C)(iii), respectively. The listed
derivatives holdings described above will comply with Rule
14.11(i)(4)(C)(iv) when calculated including the options held as part
of the investment methodology described above. The OTC derivatives will
comply with Rule 14.11(i)(4)(C)(v).
Additional Discussion
    In order to achieve its investment objective, under Normal Market
Conditions,\17\ the aggregate gross notional value of Puts may approach
100% of a Fund (including gross notional values). As noted above,
Exchange Rule 14.11(i)(4)(C)(iv)(b) prohibits a Fund from holding
listed derivatives based on any five or fewer underlying reference
assets in excess of 65% of the weight of the portfolio (including gross
notional exposures) and from holding listed derivatives based on any
single underlying reference asset in excess of 30% of the weight of its
portfolio (including gross notional exposures). The Exchange is
proposing to allow each Fund to hold up to 100% of the weight of its
respective portfolio (including gross notional exposures) in listed
derivatives based on a single underlying reference asset (the
applicable ETF) through its investment in Puts.
---------------------------------------------------------------------------

    \17\ As defined in Exchange Rule 14.11(i)(3)(E), the term
``Normal Market Conditions'' includes, but is not limited to, the
absence of trading halts in the applicable financial markets
generally; operational issues causing dissemination of inaccurate
market information or system failures; or force majeure type events
such as natural or man-made disaster, act of God, armed conflict,
act of terrorism, riot or labor disruption, or any similar
intervening circumstance.
---------------------------------------------------------------------------

    The Exchange believes that sufficient protections are in place to
protect against market manipulation of the Funds' Shares and the Puts
for several reasons: (i) The liquidity in the market for at-the-money
Puts in the underlying ETFs; (ii) the diversity, liquidity, and size of
the securities, whether equity or fixed income, underlying the ETFs
(each of which either meet the generic listing standards in Rule 14.11
or the equivalent listing rules on another national securities exchange
or have otherwise been approved for listing by the Commission); and
(iii) surveillance by the Exchange, other SROs on which the Puts are
listed and traded, and the Financial Industry Regulatory Authority
(``FINRA'') designed to detect violations of the federal securities
laws and self-regulatory organization (``SRO'') rules. The Exchange has
in place a surveillance program for transactions in ETFs to ensure the
availability of information necessary to detect and deter potential
manipulations and other trading abuses, thereby making the Shares less
readily susceptible to manipulation. Further, the Exchange believes
that because the assets in each Fund's portfolio, which are comprised
primarily of Puts, will be acquired in extremely liquid and highly
regulated markets,\18\ the Shares are less readily susceptible to
manipulation.
---------------------------------------------------------------------------

    \18\ All exchange-listed securities that the Funds may hold will
trade on a market that is a member of the Intermarket Surveillance
Group (``ISG'') and the Funds will not hold any non-exchange-listed
equities, however, not all of the components of the portfolio for
the Funds may trade on exchanges that are members of the ISG or with
which the Exchange has in place a comprehensive surveillance sharing
agreement. For a list of the current members of ISG, see
www.isgportal.org.
---------------------------------------------------------------------------

    The Exchange believes that its surveillance procedures are adequate
to properly monitor the trading of the Shares on the Exchange during
all trading sessions and to deter and detect violations of Exchange
rules and the applicable federal securities laws. Trading of the Shares
through the Exchange will be subject to the Exchange's surveillance
procedures for derivative products, including Managed Fund Shares. The
issuer has represented to the Exchange that it will advise the Exchange
of any failure by a Fund or the related Shares to comply with the
continued listing requirements, and, pursuant to its obligations under
Section 19(g)(1) of the Act, the Exchange will surveil for compliance
with the continued listing requirements. If a Fund or the related
Shares are not in compliance with the applicable listing requirements,
then, with respect to such Fund or Shares, the Exchange will commence
delisting procedures under Exchange Rule 14.12. FINRA conducts certain
cross-market surveillances on behalf of the Exchange pursuant to a
regulatory services agreement. The Exchange is responsible for FINRA's
performance under this regulatory services agreement. If a Fund is not
in compliance with the applicable listing requirements, the Exchange
will commence delisting procedures with respect to such Fund under
Exchange Rule 14.12.
    The Exchange or FINRA, on behalf of the Exchange, will communicate
as needed regarding trading in the Shares, ETPs, futures contracts, and
exchange-traded options contracts with other market and other entities
that are members of ISG and may obtain trading information in the
Shares, futures contracts, exchange-traded options contracts, and ETPs
from such markets and other entities. In addition, the Exchange, or
FINRA, on behalf of the Exchange is able to access, as needed, trade
information for certain fixed income instruments reported to FINRA's
Trade Reporting and Compliance Engine (``TRACE''). The Exchange may
also obtain information regarding trading in the Shares, futures
contracts, exchange-traded options contracts, and ETPs from markets and
other entities that are members of ISG or with which the Exchange has
in place a comprehensive surveillance sharing agreement. In addition,
the Exchange also has a general policy prohibiting the

distribution of material, non-public information by its employees.
    As noted above, options on the associated ETFs are among the most
liquid options in their applicable market sector and derive their value
from similarly liquid and actively traded ETFs and their constituents.
The contracts trade in competitive auction markets with price and quote
transparency. The Exchange believes the highly regulated options
markets and the broad base and scope of the ETFs make securities that
derive their value from such ETFs less susceptible to market
manipulation in view of size and liquidity of the ETF components, price
and quote transparency, and arbitrage opportunities.
    The Exchange believes that the liquidity of the markets for the
ETFs and options on the ETFs is sufficiently great to deter fraudulent
or manipulative acts associated with the Funds' Shares price. The
Exchange also believes that such liquidity is sufficient to support the
creation and redemption mechanism. Coupled with the surveillance
programs described above, the Exchange does not believe that trading in
the Funds' Shares would present manipulation concerns.
    The Exchange represents that, except for the limitations on listed
derivatives in BZX Rule 14.11(i)(4)(C)(iv)(b) and the limited holdings
in fixed income securities and mutual funds that do not comply with the
holdings requirements in Rule 14.11(i)(4)(C)(ii) and 14.11(i)(4)(C)(i),
respectively, the Funds' proposed investments will satisfy, on an
initial and continued listing basis, all of the generic listing
standards under BZX Rule 14.11(i)(4)(C) and all other applicable
requirements for Managed Fund Shares under Rule 14.11(i). The Trust is
required to comply with Rule 10A-3 under the Act for the initial and
continued listing of the Shares of the Funds. A minimum of 100,000
Shares will be outstanding at the commencement of trading on the
Exchange. In addition, the Exchange represents that the Shares of the
Funds will comply with all other requirements applicable to Managed
Fund Shares, which includes the dissemination of key information such
as the Disclosed Portfolio,\19\ Net Asset Value,\20\ and the Intraday
Indicative Value,\21\ suspension of trading or removal,\22\ trading
halts,\23\ surveillance,\24\ minimum price variation for quoting and
order entry,\25\ and the information circular,\26\ as set forth in
Exchange rules applicable to Managed Fund Shares. Moreover, all of the
options contracts held by the Funds will trade on markets that are a
member of ISG or affiliated with a member of ISG or with which the
Exchange has in place a comprehensive surveillance sharing agreement.
Quotation and last sale information for U.S. exchange-listed options
contracts cleared by The Options Clearing Corporation will be available
via the Options Price Reporting Authority. The intra-day, closing and
settlement prices of exchange-traded options will be readily available
from the options exchanges, automated quotation systems, published or
other public sources, or online information services such as Bloomberg
or Reuters. Price information on Cash Equivalents is available from
major broker-dealer firms or market data vendors, as well as from
automated quotation systems, published or other public sources, or
online information services.
---------------------------------------------------------------------------

    \19\ See Rule 14.11(i)(4)(A)(ii) and 14.11(i)(4)(B)(ii).
    \20\ See Rule 14.11(i)(4)(A)(ii).
    \21\ See Rule 14.11(i)(4)(B)(i).
    \22\ See Rule 14.11(i)(4)(B)(iii).
    \23\ See Rule 14.11(i)(4)(B)(iv).
    \24\ See Rule 14.11(i)(2)(C).
    \25\ See Rule 14.11(i)(2)(B).
    \26\ See Rule 14.11(i)(6).
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that the proposal is consistent with Section
6(b) of the Act \27\ in general and Section 6(b)(5) of the Act \28\ in
particular in that it is designed to prevent fraudulent and
manipulative acts and practices, to promote just and equitable
principles of trade, to foster cooperation and coordination with
persons engaged in facilitating transactions in securities, to remove
impediments to and perfect the mechanism of a free and open market and
a national market system and, in general, to protect investors and the
public interest.
---------------------------------------------------------------------------

    \27\ 15 U.S.C. 78f.
    \28\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The Exchange believes that the proposed rule change is designed to
prevent fraudulent and manipulative acts and practices in that the
Shares of each Fund will be listed on the Exchange pursuant to the
initial and continued listing criteria in Rule 14.11(i). The Exchange
believes that its surveillance procedures are adequate to properly
monitor the trading of the Shares on the Exchange during all trading
sessions and to deter and detect violations of Exchange rules and the
applicable federal securities laws. Trading of the Shares through the
Exchange will be subject to the Exchange's surveillance procedures for
derivative products, including Managed Fund Shares. The issuer has
represented to the Exchange that it will advise the Exchange of any
failure by a Fund or the related Shares to comply with the continued
listing requirements, and, pursuant to its obligations under Section
19(g)(1) of the Act, the Exchange will surveil for compliance with the
continued listing requirements. If a Fund or the related Shares are not
in compliance with the applicable listing requirements, then, with
respect to such Fund or Shares, the Exchange will commence delisting
procedures under Exchange Rule 14.12. FINRA conducts certain cross-
market surveillances on behalf of the Exchange pursuant to a regulatory
services agreement. The Exchange is responsible for FINRA's performance
under this regulatory services agreement. If a Fund is not in
compliance with the applicable listing requirements, the Exchange will
commence delisting procedures with respect to such Fund under Exchange
Rule 14.12.
    The Exchange or FINRA, on behalf of the Exchange, will communicate
as needed regarding trading in the Shares, ETPs, futures contracts, and
exchange-traded options contracts with other market and other entities
that are members of ISG and may obtain trading information in the
Shares, futures contracts, exchange-traded options contracts, and ETPs
from such markets and other entities. In addition, the Exchange, or
FINRA, on behalf of the Exchange is able to access, as needed, trade
information for certain fixed income instruments reported to FINRA's
Trade Reporting and Compliance Engine (``TRACE''). The Exchange may
also obtain information regarding trading in the Shares, futures
contracts, exchange-traded options contracts, and ETPs from markets and
other entities that are members of ISG or with which the Exchange has
in place a comprehensive surveillance sharing agreement. In addition,
the Exchange also has a general policy prohibiting the distribution of
material, non-public information by its employees.
    The Adviser is not registered as, or affiliated with, any broker-
dealer. The Sub-Adviser is affiliated with multiple broker-dealers and
has implemented a ``fire wall'' with respect to such broker-dealers and
their personnel regarding access to information concerning the
composition and/or changes to a Fund's portfolio. In addition, Sub-
Adviser personnel who make decisions regarding a Fund's portfolio are
subject to procedures designed to prevent the use and dissemination of
material nonpublic information regarding the Fund's portfolio. All
exchange-listed options, futures contracts and ETPs held

by the Funds will be traded on U.S. exchanges, all of which are members
of ISG or are exchanges with which the Exchange has in place a
comprehensive surveillance sharing agreement.
    All statements and representations made in this filing regarding
the description of the portfolio or reference assets, limitations on
portfolio holdings or reference assets, dissemination and availability
of reference asset and intraday indicative values (as applicable), or
the applicability of Exchange rules specified in this filing shall
constitute continued listing requirements for the Shares. The issuer
has represented to the Exchange that it will advise the Exchange of any
failure by a Fund to comply with the continued listing requirements,
and, pursuant to its obligations under Section 19(g)(1) of the Act, the
Exchange will monitor for compliance with the continued listing
requirements. FINRA conducts certain cross-market surveillances on
behalf of the Exchange pursuant to a regulatory services agreement. The
Exchange is responsible for FINRA's performance under this regulatory
services agreement. If a Fund is not in compliance with the applicable
listing requirements, the Exchange will commence delisting procedures
under Rule 14.12.
    The proposed rule change is designed to promote just and equitable
principles of trade and to protect investors and the public interest in
that the Exchange will obtain a representation from the issuer of the
Shares that the NAV per Share will be calculated daily every business
day, and that the NAV will be made available to all market participants
at the same time. In addition, a large amount of information will be
publicly available regarding the Fund and the Shares, thereby promoting
market transparency.
    In addition, the Exchange believes that sufficient protections are
in place to protect against market manipulation of the Funds' Shares
and the Puts because of: (i) The liquidity in the market for at-the-
money Puts in the underlying ETFs; (ii) the diversity, liquidity, and
size of the securities, whether equity or fixed income, underlying the
ETFs (each of which either meet the generic listing standards in Rule
14.11 or the equivalent listing rules on another national securities
exchange or have otherwise been approved for listing by the
Commission); and (iii) surveillance by the Exchange, other SROs on
which the Puts are listed and traded, and the FINRA designed to detect
violations of the federal securities laws and SRO rules. Further, the
Exchange believes that because the assets in each Fund's portfolio,
which are comprised primarily of Puts, will be acquired in extremely
liquid and highly regulated markets,\29\ the Shares are less readily
susceptible to manipulation.
---------------------------------------------------------------------------

    \29\ All exchange-listed securities that the Funds may hold will
trade on a market that is a member of the ISG and the Funds will not
hold any non-exchange-listed equities or options, however, not all
of the components of the portfolio for the Funds may trade on
exchanges that are members of the ISG or with which the Exchange has
in place a comprehensive surveillance sharing agreement. For a list
of the current members of ISG, see www.isgportal.org.
---------------------------------------------------------------------------

    As noted above, options on the associated ETFs are among the most
liquid options in their applicable market sector and derive their value
from similarly liquid and actively traded ETFs and their constituents.
The contracts trade in competitive auction markets with price and quote
transparency. The Exchange believes the highly regulated options
markets and the broad base and scope of the ETFs make securities that
derive their value from such ETFs less susceptible to market
manipulation in view of size and liquidity of the ETF components, price
and quote transparency, and arbitrage opportunities.
    The Exchange believes that the liquidity of the markets for the
ETFs and options on the ETFs is sufficiently great to deter fraudulent
or manipulative acts associated with the Funds' Shares price. The
Exchange also believes that such liquidity is sufficient to support the
creation and redemption mechanism. Coupled with the surveillance
programs described above, the Exchange does not believe that trading in
the Funds' Shares would present manipulation concerns. As noted above,
the Funds may hold certain fixed income securities and mutual funds
that do not comply with the holdings requirements in Rule
14.11(i)(4)(C)(ii) and 14.11(i)(4)(C)(i), respectively, but the
Exchange does not believe that these holdings represent any substantive
policy concerns because they represent such a small portion of the
portfolio.
    The Exchange represents that, except for the limitations on listed
derivatives in BZX Rule 14.11(i)(4)(C)(iv)(b), Rule 14.11(i)(4)(C)(i),
and 14.11(i)(4)(C)(ii), the Funds' proposed investments will satisfy,
on an initial and continued listing basis, all of the generic listing
standards under BZX Rule 14.11(i)(4)(C) and all other applicable
requirements for Managed Fund Shares under Rule 14.11(i). The Trust is
required to comply with Rule 10A-3 under the Act for the initial and
continued listing of the Shares of the Funds. A minimum of 100,000
Shares will be outstanding at the commencement of trading on the
Exchange. In addition, the Exchange represents that the Shares of the
Funds will comply with all other requirements applicable to Managed
Fund Shares, which includes the dissemination of key information such
as the Disclosed Portfolio,\30\ Net Asset Value,\31\ and the Intraday
Indicative Value,\32\ suspension of trading or removal,\33\ trading
halts,\34\ surveillance,\35\ minimum price variation for quoting and
order entry,\36\ and the information circular,\37\ as set forth in
Exchange rules applicable to Managed Fund Shares. Moreover, all of the
options contracts held by the Funds will trade on markets that are a
member of ISG or affiliated with a member of ISG or with which the
Exchange has in place a comprehensive surveillance sharing agreement.
The intra-day, closing and settlement prices of exchange-traded options
will be readily available from the options exchanges, automated
quotation systems, published or other public sources, or online
information services such as Bloomberg or Reuters. Price information on
Cash Equivalents is available from major broker-dealer firms or market
data vendors, as well as from automated quotation systems, published or
other public sources, or online information services.
---------------------------------------------------------------------------

    \30\ See Rule 14.11(i)(4)(A)(ii) and 14.11(i)(4)(B)(ii).
    \31\ See Rule 14.11(i)(4)(A)(ii).
    \32\ See Rule 14.11(i)(4)(B)(i).
    \33\ See Rule 14.11(i)(4)(B)(iii).
    \34\ See Rule 14.11(i)(4)(B)(iv).
    \35\ See Rule 14.11(i)(2)(C).
    \36\ See Rule 14.11(i)(2)(B).
    \37\ See Rule 14.11(i)(6).
---------------------------------------------------------------------------

    Information regarding market price and trading volume of the Shares
will be continually available on a real-time basis throughout the day
on brokers' computer screens and other electronic services, and
quotations and last sale information will be available via the CTA
high-speed line. Quotation and last sale information for the Shares and
any ETPs it [sic] which it invests will be available via the CTA high-
speed line. Quotation and last sale information for U.S. exchange-
listed options contracts cleared by The Options Clearing Corporation
will be available via the Options Price Reporting Authority. The intra-
day, closing and settlement prices of exchange-traded portfolio assets,
including ETPs, futures and exchange-traded options contracts will be
readily available from the securities exchanges and futures exchange
trading such securities and futures, as the case may be, automated
quotation systems, published or other public sources, or online
information services such as Bloomberg or Reuters. Such price
information on fixed income portfolio

securities, including money market instruments, and other Fund assets
traded in the over-the-counter markets, including bonds and money
market instruments is available from major broker-dealer firms or
market data vendors, as well as from automated quotation systems,
published or other public sources, or online information services. The
website for the Fund will include the prospectus for the Fund and
additional data relating to NAV and other applicable quantitative
information. Moreover, prior to commencement of trading, the Exchange
will inform its Members in an information circular of the special
characteristics and risks associated with trading the Shares. If the
Exchange becomes aware that the NAV is not being disseminated to all
market participants at the same time, it will halt trading in the
Shares until such time as the NAV is available to all market
participants. With respect to trading halts, the Exchange may consider
all relevant factors in exercising its discretion to halt or suspend
trading in the Shares of the Funds. Trading also may be halted because
of market conditions or for reasons that, in the view of the Exchange,
make trading in the Shares inadvisable. These may include: (1) The
extent to which trading is not occurring in the securities and/or the
financial instruments composing the daily disclosed portfolio of each
Fund; or (2) whether other unusual conditions or circumstances
detrimental to the maintenance of a fair and orderly market are
present.
    For the above reasons, the Exchange believes that the proposed rule
change is consistent with the requirements of Section 6(b)(5) of the
Act.

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purpose of the Act. The Exchange notes that the
proposed rule change will facilitate the listing and trading of an
additional type of Managed Fund Shares that will enhance competition
among market participants, to the benefit of investors and the
marketplace.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    The Exchange has neither solicited nor received written comments on
the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Within 45 days of the date of publication of this notice in the
Federal Register or within such longer period (i) as the Commission may
designate up to 90 days of such date if it finds such longer period to
be appropriate and publishes its reasons for so finding or (ii) as to
which the Exchange consents, the Commission will: (a) By order approve
or disapprove such proposed rule change, or (b) institute proceedings
to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to [email protected]. Please include
File Number SR-CboeBZX-2018-078 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.

All submissions should refer to File Number SR-CboeBZX-2018-078. This
file number should be included on the subject line if email is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's internet website (http://www.sec.gov/rules/sro.shtml).
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than those
that may be withheld from the public in accordance with the provisions
of 5 U.S.C. 552, will be available for website viewing and printing in
the Commission's Public Reference Room, 100 F Street NE, Washington, DC
20549 on official business days between the hours of 10 a.m. and 3 p.m.
Copies of the filing also will be available for inspection and copying
at the principal office of the Exchange. All comments received will be
posted without change. Persons submitting comments are cautioned that
we do not redact or edit personal identifying information from comment
submissions. You should submit only information that you wish to make
available publicly. All submissions should refer to File Number SR-
CboeBZX-2018-078 and should be submitted on or before November 15,
2018.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\38\
---------------------------------------------------------------------------

    \38\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Eduardo A. Aleman,
Assistant Secretary.
[FR Doc. 2018-23278 Filed 10-24-18; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register: November 29, 2005 (Volume 70, Number 228)]
[Notices]
[Page 71541]
[DOCID:fr29no05-69]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[FEMA-1609-DR]

Florida; Amendment No. 5 to Notice of a Major Disaster
Declaration

AGENCY: Federal Emergency Management Agency, Department of Homeland
Security.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster for the
State of Florida (FEMA-1609-DR), dated October 24, 2005, and related
determinations.

DATES: Effective November 18, 2005.

FOR FURTHER INFORMATION CONTACT: Magda Ruiz, Recovery Division, Federal
Emergency Management Agency, Washington, DC 20472,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the incident
period for this disaster is closed effective November 18, 2005.

(The following Catalog of Federal Domestic Assistance Numbers (CFDA)
are to be used for reporting and drawing funds: 97.030, Community
Disaster Loans; 97.031, Cora Brown Fund Program; 97.032, Crisis
Counseling; 97.033, Disaster Legal Services Program; 97.034,
Disaster Unemployment Assistance (DUA); 97.046, Fire Management
Assistance; 97.048, Individuals and Households Housing; 97.049,
Individuals and Households Disaster Housing Operations; 97.050,
Individuals and Households Program--Other Needs; 97.036, Public
Assistance Grants; 97.039, Hazard Mitigation Grant Program.)

R. David Paulison,
Acting Director, Federal Emergency Management Agency, Department of
Homeland Security.
 [FR Doc. E5-6658 Filed 11-28-05; 8:45 am]


Episode 6000 Data APPENDIX B  4  1 Page 1 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

0.40Classicals, Method 130.2Classicals, 130.2 HARDNESS, MG/ LHARDNESS, L 5 10 50 100 0.005 0.050 0.500 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 Classicals, Method 350.3Classicals, 350.3 AMMONIA AS NITROGEN, MG/ LAMMONIA L Metals, Method ICP/ MSMetals, MS Cd 111, pptCd ppt Metals, Method ICP/ MSMetals, MS Pb 206, pptPb ppt Classicals, Method 160.2Classicals, 160.2 TOTAL SUSPENDED SOLIDS, MG/ LTOTAL L 0.5 5.0 50.0 0.050 0.500 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 Classicals, Method 365.2Classicals, 365.2 TOTAL PHOSPHORUS, MG/ LTOTAL L Metals, Method ICP/ MSMetals, MS Cu 63, pptCu ppt Metals, Method ICP/ MSMetals, MS Pb 207, pptPb ppt Classicals, Method 1677Classicals, 1677 WAD CYANIDE, UG/ LWAD L 0.5 1.0 5.0 10.0 Metals, Method ICP/ MSMetals, MS Ag 107, pptAg ppt 0.1 1.0 10.0 100.0 1000.0 Metals, Method ICP/ MSMetals, MS Ni 60, pptNi ppt 0.1 1.0 10.0 100.0 1000.0 Metals, Method ICP/ MSMetals, MS Pb 208, pptPb ppt 0.1 1.0 10.0 100.0 1000.0 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.050 0.010 0.005 0.001 100.0 50.0 10.0 5.0 1.0 0.5 100.0 50.0 10.0 5.0 1.0 0.5 0.30 0.20 0.10 0.09 0.08 0.07 0.06 100.0 50.0 10.0 5.0 1.0 0.5 100 50 10 5 100 50 10 5 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.006 0.005 0.004 0.003 0.002 0.005 100 50 10 5 100 50 10 5 1 Log 10 of Observed Standard Deviation Log 10 of Spike Concentration 50.0 Episode 6000 Data Page 2 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

500 Log 10 of Observed Standard Deviation 100.0 100 50.0 Metals, Method ICP/ MSMetals, MS Sb 123, pptSb ppt 50 Metals, Method ICP/ MSMetals, MS Se 82, pptSe ppt Metals, Method ICP/ MSMetals, MS Tl 205, pptTl ppt 10.0 5.0 100 10 5 1.0 50 0.5 1 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 Metals, Method ICP/ MSMetals, MS Zn 66, pptZn ppt 100 Metals, Method 1620Metals, 1620 ANTIMONY, UG/ LANTIMONY, L 100 1.0 50 0.9 50 0.8 0.7 0.6 10 10 Metals, Method 1620Metals, 1620 ALUMINUM, UG/ LALUMINUM, L 0.5 5 5 0.4 0.1 1.0 10.0 100.0 1000.0 1 5 10 50 100 500 0.1 0.5 5.0 50.0 Metals, Method 1620Metals, 1620 BERYLLIUM, UG/ LBERYLLIUM, L 1.0 1.0 0.9 1.0 0.8 0.7 0.5 0.6 0.5 0.5 0.4 0.3 Metals, Method 1620Metals, 1620 ARSENIC, UG/ LARSENIC, L Metals, Method 1620Metals, 1620 BARIUM, UG/ LBARIUM, L 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 5.0 50.0 0.05 0.50 5.00 50.00 0.10 10 Metals, Method 1620Metals, 1620 BORON, UG/ LBORON, L Metals, Method 1620Metals, 1620 CADMIUM, UG/ LCADMIUM, L 10 0.05 55 Metals, Method 1620Metals, 1620 CALCIUM, UG/ LCALCIUM, L 5 10 50 100 500 0.05 0.50 5.00 5 10 50 100 500 Mon Mar 18 16: 24: 15 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 3 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

10 Metals, Method 1620Metals, 1620 CHROMIUM, UG/ LCHROMIUM, L 0.5 0.1 0.1 0.5 5.0 50.0 100 50 10 5 1 5 10 50 100 500 Metals, Method 1620Metals, 1620 IRON, UG/ LIRON, L 1.0 0.5 Metals, Method 1620Metals, 1620 MANGANESE, UG/ LMANGANESE, L 0.1 0.5 5.0 50.0 1.0 0.5 Metals, Method 1620Metals, 1620 SELENIUM, UG/ LSELENIUM, L 0.5 1.0 5.0 10.0 50.0 Metals, Method 1620Metals, 1620 COBALT, UG/ LCOBALT, L 10 5 1 5 10 50 100 500 1.0 0.5 Metals, Method 1620Metals, 1620 LEAD, UG/ LLEAD, L 0.5 5.0 50.0 2.0 1.0 0.9 0.8 0.7 0.6 0.5 0.4 Metals, Method 1620Metals, 1620 MOLYBDENUM, UG/ LMOLYBDENUM, L 0.5 5.0 50.0 6 5 4 3 2 Metals, Method 1620Metals, 1620 SILVER, UG/ LSILVER, L 0.5 5.0 50.0 500.0 Metals, Method 1620Metals, 1620 COPPER, UG/ LCOPPER, L 5 0.5 5.0 50.0 60 50 40 30 20 Metals, Method 1620Metals, 1620 MAGNESIUM, UG/ LMAGNESIUM, L 5 10 50 100 500 5000 10 5 Metals, Method 1620Metals, 1620 NICKEL, UG/ LNICKEL, L 5 10 50 100 500 70 60 50 40 30 20 5 10 50 100 500 5000 Metals, Method 1620Metals, 1620 SODIUM, UG/ LSODIUM, L Log 10 of Observed Standard Deviation Mon Mar 18 16: 24: 28 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 4 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation 0.7 0.6 0.5 0.4 0.3 0.2 Metals, Method 1620Metals, 1620 THALLIUM, UG/ LTHALLIUM, L 0.1 0.5 5.0 50.0 10 5 Metals, Method 1620Metals, 1620 VANADIUM, UG/ LVANADIUM, L 1 5 10 50 100 500 10 5 1 0.5 5.0 50.0 500.0 Metals, Method 200.8Metals, 200.8 ALUMINUM, UG/ LALUMINUM, L 0.100 0.050 0.010 0.005 0.01 0.10 1.00 10.00 Metals, Method 200.8Metals, 200.8 BARIUM, UG/ LBARIUM, L 4.0 3.0 3.0 2.0 2.0 1.0 Metals, Method 1620Metals, 1620 TIN, UG/ LTIN, L 1.0 0.9 0.9 0.8 0.8 0.7 0.7 0.6 0.6 Metals, Method 1620Metals, 1620 TITANIUM, UG/ LTITANIUM, L 0.5 5.0 50.0 0.5 5.0 50.0 10.0 5.0 1.0 0.5 Metals, Method 1620Metals, 1620 YTTRIUM, UG/ LYTTRIUM, L 1.0 0.5 Metals, Method 1620Metals, 1620 ZINC, UG/ LZINC, L 0.1 0.5 5.0 50.0 0.5 5.0 50.0 0.100 Metals, Method 200.8Metals, 200.8 ANTIMONY, UG/ LANTIMONY, L 1.00 0.050 0.50 0.010 0.005 0.10 0.05 0.001 0.01 0.10 1.00 10.00 0.1 1.0 10.0 100.0 Metals, Method 200.8Metals, 200.8 ARSENIC, UG/ LARSENIC, L 0.100 0.050 Metals, Method 200.8Metals, 200.8 BERYLLIUM, UG/ LBERYLLIUM, L 0.010 0.005 0.010 0.005 0.001 0.005 0.050 0.500 5.000 0.001 0.005 0.050 0.500 Metals, Method 200.8Metals, 200.8 CADMIUM, UG/ LCADMIUM, L Mon Mar 18 16: 24: 42 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 5 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

0.50 Metals, Method 200.8Metals, 200.8 CHROMIUM, UG/ LCHROMIUM, L Metals, Method 200.8Metals, 200.8 COBALT, UG/ LCOBALT, L Metals, Method 200.8Metals, 200.8 COPPER, UG/ LCOPPER, L 0.0100 0.0050 0.10 0.10 0.05 0.05 0.0010 0.0005 0.01 0.05 0.50 5.00 0.0005 0.0050 0.0500 0.5000 0.01 0.05 0.50 5.00 0.50 Metals, Method 200.8Metals, 200.8 LEAD, UG/ LLEAD, L 0.050 Metals, Method 200.8Metals, 200.8 MANGANESE, UG/ LMANGANESE, L 0.100 0.050 0.10 0.010 0.05 0.010 0.005 0.005 0.01 0.05 0.50 5.00 50.00 0.001 0.005 0.050 0.500 0.005 0.050 0.500 5.000 Metals, Method 200.8Metals, 200.8 MERCURY, UG/ LMERCURY, L Log 10 of Observed Standard Deviation 0.1000 0.0500 0.0100 0.0050 0.0010 0.0005 0.0005 0.0050 0.0500 0.5000 Metals, Method 200.8Metals, 200.8 MOLYBDENUM, UG/ LMOLYBDENUM, L 0.010 0.005 0.001 0.0005 0.0050 0.0500 0.5000 Metals, Method 200.8Metals, 200.8 SILVER, UG/ LSILVER, L Mon Mar 18 16: 24: 55 2002 1.000 0.500 Metals, Method 200.8Metals, 200.8 NICKEL, UG/ LNICKEL, L 1.00 0.50 0.100 0.050 0.10 0.010 0.05 0.005 0.01 0.10 1.00 10.00 0.05 0.50 5.00 50.00 Metals, Method 200.8Metals, 200.8 SELENIUM, UG/ LSELENIUM, L Metals, Method 200.8Metals, 200.8 THALLIUM, UG/ LTHALLIUM, L 0.0100 0.0010 0.0050 0.0005 0.0010 0.0005 Metals, Method 200.8Metals, 200.8 THORIUM, UG/ LTHORIUM, L 0.0001 0.0005 0.0050 0.0500 0.001 0.010 0.100 1.000 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 6 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

5.0 0.00100 0.00050 0.00010 0.00005 0.500 0.100 0.050 0.010 0.005 0.05 0.100 0.050 0.010 0.005 0.05 0.50 0.10 0.05 0.01 Metals, Method 200.8Metals, 200.8 URANIUM, UG/ LURANIUM, L 0.0001 0.0010 0.0100 0.1000 0.50 5.00 0.50 5.00 0.01 0.05 0.50 5.00 Organics, Method 502.2 ELCDOrganics, ELCD 1,1,1,2 TETRACHLOROETHANE, UG/ L1,1,1,2 L Organics, Method 502.2 ELCDOrganics, ELCD 1,1,2 TRICHLOROETHANE, UG/ L1,1,2 L Organics, Method 502.2 ELCDOrganics, ELCD 1,2,3 TRICHLOROBENZENE, UG/ L1,2,3 L 1.0 0.5 0.1 0.500 0.100 0.050 0.010 0.005 0.05 0.500 0.100 0.050 0.010 0.005 0.05 0.50 0.10 0.05 0.01 Metals, Method 200.8Metals, 200.8 VANADIUM, UG/ LVANADIUM, L 0.1 1.0 10.0 100.0 Organics, Method 502.2 ELCDOrganics, ELCD 1,1,1 TRICHLOROETHANE, UG/ L1,1,1 L 0.50 5.00 Organics, Method 502.2 ELCDOrganics, ELCD 1,1 DICHLOROETHANE, UG/ L1,1 L 0.50 5.00 Organics, Method 502.2 ELCDOrganics, ELCD 1,2,4 TRICHLOROBENZENE, UG/ L1,2,4 L 0.001 0.010 0.100 1.000 10.000 Metals, Method 200.8Metals, 200.8 ZINC, UG/ LZINC, L 1.0 0.5 0.1 0.5 5.0 50.0 1.00 0.50 0.10 0.05 Organics, Method 502.2 ELCDOrganics, ELCD 1,1,2,2 TCE+ 1,2,3 TCP, UG/ L1,1,2,2 L 1 510 0.500 0.100 0.050 0.010 0.005 0.1 0.5 1.0 5.0 10.0 Organics, Method 502.2 ELCDOrganics, ELCD 1,1 DICHLOROETHENE, UG/ L1,1 L 0.100 0.050 0.010 0.005 0.5 1.0 5.0 10.0 Organics, Method 502.2 ELCDOrganics, ELCD 1,2 DIBROMOETHANE, UG/ L1,2 L Log 10 of Observed Standard Deviation Mon Mar 18 16: 25: 09 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 7 of 32 Standard Deviations vs Spike Concentrations ( Log 10 Scale) 1.000 0.500 0.500 0.500 Organics, Method 502.2 ELCDOrganics, ELCD 1,2 DICHLOROBENZENE, UG/ L1,2 L Organics, Method 502.2 ELCDOrganics, ELCD 1,2 DICHLOROETHANE, UG/ L1,2 L Organics, Method 502.2 ELCDOrganics, ELCD 1,2 DICHLOROPROPANE, UG/ L1,2 L 0.100 0.100 0.100 0.050 0.050 0.050 0.010 0.010 0.010 0.005 0.005 0.005 0.05 0.50 5.00 0.05 0.50 5.00 0.05 0.50 5.00 0.500 Organics, Method 502.2 ELCDOrganics, ELCD 1,3 DICHLOROBENZENE, UG/ L1,3 L Organics, Method 502.2 ELCDOrganics, ELCD 1,3 DICHLOROPROPANE, UG/ L1,3 L 0.500 0.100 0.100 0.100 0.050 0.050 0.050 0.010 0.010 0.010 0.005 0.005 0.005 Organics, Method 502.2 ELCDOrganics, ELCD 1,4 DICHLOROBENZENE, UG/ L1,4 L 0.01 0.05 0.50 5.00 0.1 0.5 1.0 5.0 10.0 0.05 0.50 5.00 1.00 1.00 Organics, Method 502.2 ELCDOrganics, ELCD 4 CHLOROTOLUENE, UG/ L4 L 0.50 0.50 Organics, Method 502.2 ELCDOrganics, ELCD 2 CHLOROTOLUENE, UG/ L2 L 0.50 0.10 0.10 0.10 0.05 0.05 0.05 0.01 Organics, Method 502.2 ELCDOrganics, ELCD BROMOBENZENE, UG/ LBROMOBENZENE, L 0.05 0.50 5.00 0.05 0.50 5.00 0.5 1.0 5.0 10.0 0.500 Organics, Method 502.2 ELCDOrganics, ELCD BROMOCHLOROMETHANE, UG/ LBROMOCHLOROMETHANE, L 0.500 0.100 Organics, Method 502.2 ELCDOrganics, ELCD BROMODICHLOROMETHANE, UG/ LBROMODICHLOROMETHANE, L 0.100 0.100 0.050 0.050 0.050 0.010 0.010 0.010 0.005 0.005 Organics, Method 502.2 ELCDOrganics, ELCD BROMOFORM, UG/ LBROMOFORM, L Log 10 of Observed Standard Deviation 0.005 0.1 0.5 1.0 5.0 10.0 0.05 0.50 5.00 0.5 1.0 5.0 10.0 Mon Mar 18 16: 25: 23 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 8 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

0.500 0.20 0.10 0.09 0.08 0.07 Organics, Method 502.2 ELCDOrganics, ELCD BROMOMETHANE, UG/ LBROMOMETHANE, L 1 510 0.100 0.050 0.010 0.005 0.5 1.0 5.0 10.0 Organics, Method 502.2 ELCDOrganics, ELCD CHLOROETHANE, UG/ LCHLOROETHANE, L 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 502.2 ELCDOrganics, ELCD CIS 1,2 DCE+ 2,2 DCP, UG/ LCIS L 0.1 0.5 1.0 5.0 10.0 0.500 0.100 0.050 0.010 0.005 Organics, Method 502.2 ELCDOrganics, ELCD DIBROMOMETHANE, UG/ LDIBROMOMETHANE, L 0.1 0.5 1.0 5.0 10.0 1.000 0.500 0.100 0.050 0.010 0.005 0.500 0.100 0.050 0.010 0.005 0.05 0.500 0.100 0.050 0.010 0.005 0.001 0.05 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 502.2 ELCDOrganics, ELCD CARBONTET+ 1,1 DCP, UG/ LCARBONTET+ L Organics, Method 502.2 ELCDOrganics, ELCD CHLOROBENZENE, UG/ LCHLOROBENZENE, L 0.100 0.050 0.010 0.005 0.1 0.5 1.0 5.0 10.0 0.1 0.5 1.0 5.0 10.0 Organics, Method 502.2 ELCDOrganics, ELCD CHLOROFORM, UG/ LCHLOROFORM, L 0.10 0.05 0.01 0.50 5.00 0.01 0.05 0.50 5.00 Organics, Method 502.2 ELCDOrganics, ELCD CHLOROMETHANE, UG/ LCHLOROMETHANE, L Organics, Method 502.2 ELCDOrganics, ELCD CIS 1,3 DICHLOROPROPENE, UG/ LCIS L 0.100 0.050 0.010 0.005 0.001 0.50 5.00 0.1 0.5 1.0 5.0 10.0 Organics, Method 502.2 ELCDOrganics, ELCD DIBROMOCHLOROMETHANE, UG/ LDIBROMOCHLOROMETHANE, L Organics, Method 502.2 ELCDOrganics, ELCD DICHLORODIFLUOROMETHANE, UG/ LDICHLORODIFLUOROMETHANE, L 0.500 0.100 0.050 0.010 0.005 0.05 0.50 5.00 0.001 0.010 0.100 1.000 10.000 Organics, Method 502.2 ELCDOrganics, ELCD HEXACHLOROBUTADIENE, UG/ LHEXACHLOROBUTADIENE, L Log 10 of Observed Standard Deviation Mon Mar 18 16: 25: 36 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 9 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation 1.00 0.50 0.10 0.05 Organics, Method 502.2 ELCDOrganics, ELCD METHYLENE CHLORIDE, UG/ LMETHYLENE L 0.05 0.50 5.00 0.500 0.100 0.050 0.010 0.005 Organics, Method 502.2 ELCDOrganics, ELCD TRANS 1,3 DICHLOROPROPENE, UG/ LTRANS L 0.05 0.50 5.00 0.10 0.05 Organics, Method 502.2 ELCDOrganics, ELCD VINYL CHLORIDE, UG/ LVINYL L 0.5 1.0 5.0 10.0 0.50 0.10 0.05 0.01 Organics, Method 502.2 PIDOrganics, PID 1,2,4 TRIMETHYLBENZENE, UG/ L1,2,4 L 0.05 0.50 5.00 0.500 0.100 0.050 0.010 0.005 0.05 0.50 5.00 Organics, Method 502.2 ELCDOrganics, ELCD TETRACHLOROETHENE, UG/ LTETRACHLOROETHENE, L 0.500 0.100 0.050 0.010 0.005 0.001 0.05 0.50 5.00 Organics, Method 502.2 ELCDOrganics, ELCD TRICHLOROETHENE, UG/ LTRICHLOROETHENE, L 0.10 0.05 0.01 0.01 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID 1,2,3 TRICHLOROBENZENE, UG/ L1,2,3 L 0.50 0.10 0.05 0.01 0.1 0.5 1.0 5.0 10.0 Organics, Method 502.2 PIDOrganics, PID 1,2 DICHLOROBENZENE, UG/ L1,2 L 0.500 0.100 0.050 0.010 0.005 Organics, Method 502.2 ELCDOrganics, ELCD TRANS 1,2 DICHLOROETHENE, UG/ LTRANS L 0.05 0.50 5.00 0.50 0.10 0.05 Organics, Method 502.2 ELCDOrganics, ELCD TRICHLOROFLUOROMETHANE, UG/ LTRICHLOROFLUOROMETHANE, L 0.5 1.0 5.0 10.0 0.50 0.10 0.05 Organics, Method 502.2 PIDOrganics, PID 1,2,4 TRICHLOROBENZENE, UG/ L1,2,4 L 0.05 0.50 5.00 1.00 0.50 0.10 0.05 0.01 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID 1,3,5 TMB+ 4 CHLOROTOLUENE, UG/ L1,3,5 L Mon Mar 18 16: 25: 49 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 0.50 0.50 0.500 0.100 Log 10 of Observed Standard Deviation Organics, Method 502.2 PIDOrganics, PID 1,3 DICHLOROBENZENE, UG/ L1,3 L 0.10 0.05 0.01 0.05 0.50 5.00 0.100 0.050 0.010 0.005 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID BROMOBENZENE, UG/ LBROMOBENZENE, L 0.50 0.10 0.05 0.01 Organics, Method 502.2 PIDOrganics, PID ETHYLBENZENE, UG/ LETHYLBENZENE, L 0.05 0.50 5.00 1.000 0.500 0.100 0.050 0.010 0.005 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID M+ P XYLENE, UG/ LM+ L Organics, Method 502.2 PIDOrganics, PID 2 CHLOROTOLUENE, UG/ L2 L Page 10 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 502.2 PIDOrganics, PID BENZENE, UG/ LBENZENE, L 0.050 0.10 0.05 0.010 0.005 0.05 0.50 5.00 0.05 0.50 5.00 0.50 0.50 0.10 Organics, Method 502.2 PIDOrganics, PID CHLOROBENZENE, UG/ LCHLOROBENZENE, L 0.10 0.05 0.05 0.01 0.05 0.50 5.00 0.1 0.5 1.0 5.0 10.0 Organics, Method 502.2 PIDOrganics, PID CIS 1,3 DICHLOROPROPENE, UG/ LCIS L 0.5000.50 0.100 0.050 0.10 0.010 0.005 0.05 0.01 0.05 0.50 5.00 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID HEXCHLOBUTADIENE+ NAPHTHALENE, UG/ LHEXCHLOBUTADIENE+ L Organics, Method 502.2 PIDOrganics, PID ISOPROPYLBENZENE, UG/ LISOPROPYLBENZENE, L 0.50 Organics, Method 502.2 PIDOrganics, PID N BUTYLBENZENE, UG/ LN L 0.50 0.10 0.10 0.05 0.05 0.01 0.01 0.05 0.50 5.00 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID N PROPYLBENZENE, UG/ LN L Mon Mar 18 16: 26: 02 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 1.00 0.50 0.10 0.05 0.01 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID O XYLENE+ STYRENE, UG/ LO L 0.50 0.10 0.05 0.01 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID TERT BUTYLBENZENE, UG/ LTERT L 0.50 0.10 0.05 Organics, Method 502.2 PIDOrganics, PID TRANS 1,3 DICHLOROPROPENE, UG/ LTRANS L 0.1 0.5 1.0 5.0 10.0 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,1,1 TRICHLOROETHANE, UG/ L1,1,1 L 1.00 0.50 0.10 0.05 0.01 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID P ISOPROPTOL+ 1,4 DCB, UG/ LP L 0.50 0.10 0.05 Organics, Method 502.2 PIDOrganics, PID TETRACHLOROETHENE, UG/ LTETRACHLOROETHENE, L 0.5 1.0 5.0 10.0 0.50 0.10 0.05 0.01 0.1 0.5 1.0 5.0 10.0 Organics, Method 502.2 PIDOrganics, PID TRICHLOROETHENE, UG/ LTRICHLOROETHENE, L 10.00 5.00 1.00 0.50 0.10 0.05 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,1,2,2 TETRACHLOROETHANE, UG/ L1,1,2,2 L 0.50 0.10 0.05 0.01 0.05 0.50 5.00 Page 11 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 502.2 PIDOrganics, PID SEC BUTYLBENZENE, UG/ LSEC L 0.500 0.100 0.050 0.010 0.005 0.05 0.50 5.00 Organics, Method 502.2 PIDOrganics, PID TOLUENE, UG/ LTOLUENE, L 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,1,1,2 TETRACHLOROETHANE, UG/ L1,1,1,2 L 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 1,1,2 TRICHLOROETHANE, UG/ L1,1,2 L 0.5 1.0 5.0 50.0 Mon Mar 18 16: 26: 16 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,1 DICHLOROETHANE, UG/ L1,1 L 10.000 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,1 DICHLOROPROPENE, UG/ L1,1 L 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,2,4 TRICHLOROBENZENE, UG/ L1,2,4 L 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 1,2 DIBROMOETHANE, UG/ L1,2 L 0.5 1.0 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 1,1 DICHLOROETHENE, UG/ L1,1 L 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 1,2,3 TRICHLOROBENZENE, UG/ L1,2,3 L 0.5 5.0 50.0 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 524.2Organics, 524.2 1,2,4 TRIMETHYLBENZENE, UG/ L1,2,4 L 0.1 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.1 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,2 DICHLOROBENZENE, UG/ L1,2 L 5 4 3 2 Page 12 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 524.2Organics, 524.2 1,1 DICHLOROPROPANONE, UG/ L1,1 L 50 100 5.00 1.00 0.50 0.10 0.05 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,2,3 TRICHLOROPROPANE, UG/ L1,2,3 L 10.0 5.0 1.0 0.5 Organics, Method 524.2Organics, 524.2 1,2 DIBROMO 3 CHLOROPROPANE, UG/ L1,2 L 5 10 50 100 5.00 1.00 0.50 0.10 0.05 0.01 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,2 DICHLOROETHANE, UG/ L1,2 L Mon Mar 18 16: 26: 29 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.000 Log 10 of Observed Standard Deviation 5.00 Organics, Method 524.2Organics, 524.2 1,2 DICHLOROPROPANE, UG/ L1,2 L 5.000 1.000 1.00 0.500 0.50 0.100 0.050 0.10 0.05 0.010 0.005 Organics, Method 524.2Organics, 524.2 1,3,5 TRIMETHYLBENZENE, UG/ L1,3,5 L 0.5 1.0 5.0 50.0 0.1 0.5 5.0 50.0 5.00 Organics, Method 524.2Organics, 524.2 1,3 DICHLOROPROPANE, UG/ L1,3 L 10.000 5.000 1.00 1.000 0.50 0.500 0.100 0.10 0.050 0.05 0.010 0.005 0.01 0.5 5.0 50.0 0.1 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 1,4 DICHLOROBENZENE, UG/ L1,4 L 10.00 5.00 Organics, Method 524.2Organics, 524.2 2,2 DICHLOROPROPANE, UG/ L2,2 L 5.0 1.00 1.0 0.50 0.5 0.10 0.05 1 5 10 50100 5 10 50 100 Organics, Method 524.2Organics, 524.2 2 BUTANONE, UG/ L2 L Organics, Method 524.2Organics, 524.2 2 HEXANONE, UG/ L2 L 10.0 10.0 5.0 5.0 1.0 1.0 0.5 0.5 0.1 Organics, Method 524.2Organics, 524.2 2 NITROPROPANE, UG/ L2 L 5 10 50100 5 10 50 100 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.1 0.5 5.0 50.0 Page 13 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 524.2Organics, 524.2 1,3 DICHLOROBENZENE, UG/ L1,3 L 100.00 10.00 1.00 0.10 0.01 Organics, Method 524.2Organics, 524.2 1 CHLOROBUTANE, UG/ L1 L 0.1 0.5 5.0 50.0 10.000 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.1 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 2 CHLOROTOLUENE, UG/ L2 L 10.00 1.00 0.10 0.01 Organics, Method 524.2Organics, 524.2 4 CHLOROTOLUENE, UG/ L4 L 0.1 0.5 5.0 50.0 Mon Mar 18 16: 26: 42 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 524.2Organics, 524.2 4 ISOPROPYLTOLUENE, UG/ L4 L 0.1 0.5 5.0 50.0 5.0 1.0 0.5 Organics, Method 524.2Organics, 524.2 ACRYLONITRILE, UG/ LACRYLONITRILE, L 5 10 50 100 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 BROMOBENZENE, UG/ LBROMOBENZENE, L 0.5 5.0 50.0 5.00 1.00 0.50 0.10 0.05 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 BROMOFORM, UG/ LBROMOFORM, L 10.0 5.0 1.0 0.5 Organics, Method 524.2Organics, 524.2 4 METHYL 2 PENTANONE, UG/ L4 L 5 10 50 100 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 ALLYL CHLORIDE, UG/ LALLYL L 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 BROMOCHLOROMETHANE, UG/ LBROMOCHLOROMETHANE, L 0.5 1.0 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 BROMOMETHANE, UG/ LBROMOMETHANE, L 0.5 5.0 50.0 10.0 5.0 1.0 0.5 Page 14 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 524.2Organics, 524.2 ACETONE, UG/ LACETONE, L 5 10 50 100 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 524.2Organics, 524.2 BENZENE, UG/ LBENZENE, L 0.1 1.0 10.0 100.0 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 BROMODICHLOROMETHANE, UG/ LBROMODICHLOROMETHANE, L 10.00 5.00 1.00 0.50 0.10 0.05 0.01 Organics, Method 524.2Organics, 524.2 CARBON DISULFIDE, UG/ LCARBON L 0.1 0.5 5.0 50.0 Mon Mar 18 16: 26: 55 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.00 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 CARBON TETRACHLORIDE, UG/ LCARBON L 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 CHLOROETHANE, UG/ LCHLOROETHANE, L 0.5 1.0 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 CIS 1,2 DICHLOROETHENE, UG/ LCIS L 0.5 1.0 5.0 50.0 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 DIBROMOMETHANE, UG/ LDIBROMOMETHANE, L 0.5 1.0 5.0 50.0 5.0 1.0 0.5 Organics, Method 524.2Organics, 524.2 CHLOROACETONITRILE, UG/ LCHLOROACETONITRILE, L 10 50 100 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 CHLOROFORM, UG/ LCHLOROFORM, L 0.5 5.0 50.0 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 CIS 1,3 DICHLOROPROPENE, UG/ LCIS L 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 DICHLORODIFLUOROMETHANE, UG/ LDICHLORODIFLUOROMETHANE, L 0.5 1.0 5.0 50.0 Page 15 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 524.2Organics, 524.2 CHLOROBENZENE, UG/ LCHLOROBENZENE, L 1.00 0.10 0.01 0.1 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 CHLOROMETHANE, UG/ LCHLOROMETHANE, L 0.5 5.0 50.0 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 DIBROMOCHLOROMETHANE, UG/ LDIBROMOCHLOROMETHANE, L 0.5 1.0 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 DIETHYL ETHER, UG/ LDIETHYL L 0.5 1.0 5.0 50.0 Log 10 of Observed Standard Deviation Mon Mar 18 16: 27: 09 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 ETHYL METHACRYLATE, UG/ LETHYL L 0.5 1.0 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 HEXACHLOROETHANE, UG/ LHEXACHLOROETHANE, L 0.5 5.0 50.0 5.0 1.0 0.5 Organics, Method 524.2Organics, 524.2 METHACRYLONITRILE, UG/ LMETHACRYLONITRILE, L 5 10 50 100 10.00 5.00 1.00 0.50 0.10 0.05 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 METHYLACRYLATE, UG/ LMETHYLACRYLATE, L 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 ETHYLBENZENE, UG/ LETHYLBENZENE, L 10.00 1.00 0.10 0.01 Organics, Method 524.2Organics, 524.2 ISOPROPYLBENZENE, UG/ LISOPROPYLBENZENE, L 0.1 0.5 5.0 50.0 10.000 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 METHYL IODIDE, UG/ LMETHYL L 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 METHYLENE CHLORIDE, UG/ LMETHYLENE L 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 Page 16 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 524.2Organics, 524.2 HEXACHLOROBUTADIENE, UG/ LHEXACHLOROBUTADIENE, L 0.5 5.0 50.0 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 524.2Organics, 524.2 M+ P XYLENE, UG/ LM+ L 0.1 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 METHYL TERT BUTYL ETHER, UG/ LMETHYL L 5.00 1.00 0.50 0.10 0.05 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 METHYLMETHACRYLATE, UG/ LMETHYLMETHACRYLATE, L Log 10 of Observed Standard Deviation Mon Mar 18 16: 27: 22 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 524.2Organics, 524.2 N BUTYLBENZENE, UG/ LN L 0.1 0.5 5.0 50.0 10.000 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 O XYLENE, UG/ LO L 10.000 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.1 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 STYRENE, UG/ LSTYRENE, L 10.00 1.00 0.10 0.01 Organics, Method 524.2Organics, 524.2 TOLUENE, UG/ LTOLUENE, L 0.1 0.5 5.0 50.0 Mon Mar 18 16: 27: 36 2002 10.00 5.00 1.00 0.50 0.10 0.05 Organics, Method 524.2Organics, 524.2 N PROPYLBENZENE, UG/ LN L 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 PENTACHLOROETHANE, UG/ LPENTACHLOROETHANE, L 10.000 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.1 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 TERT BUTYLBENZENE, UG/ LTERT L 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 TRANS 1,2 DICHLOROETHENE, UG/ LTRANS L Log 10 of Spike Concentration 10.00 5.00 1.00 0.50 0.10 0.05 Page 17 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 524.2Organics, 524.2 NAPHTHALENE, UG/ LNAPHTHALENE, L 0.5 5.0 50.0 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 524.2Organics, 524.2 SEC BUTYLBENZENE, UG/ LSEC L 0.1 0.5 5.0 50.0 10.00 5.00 1.00 0.50 0.10 0.05 0.01 0.5 5.0 50.0 Organics, Method 524.2Organics, 524.2 TETRACHLOROETHENE, UG/ LTETRACHLOROETHENE, L 5.00 1.00 0.50 0.10 0.05 0.01 0.5 1.0 5.0 50.0 Organics, Method 524.2Organics, 524.2 TRANS 1,3 DICHLOROPROPENE, UG/ LTRANS L c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.00 Log 10 of Observed Standard Deviation 5.0 Organics, Method 524.2Organics, 524.2 TRANS 1,4 DICHLORO 2 BUTENE, UG/ LTRANS L 5.00 Organics, Method 524.2Organics, 524.2 TRICHLOROETHENE, UG/ LTRICHLOROETHENE, L 10.00 5.00 1.00 0.50 1.00 1.0 0.50 0.10 0.5 0.05 0.10 0.05 0.01 Page 18 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 524.2Organics, 524.2 TRICHLOROFLUOROMETHANE, UG/ LTRICHLOROFLUOROMETHANE, L 5 10 50 100 0.5 5.0 50.0 0.5 1.0 5.0 50.0 10.00 Organics, Method 524.2Organics, 524.2 XYLENE ( TOTAL), UG/ LXYLENE L 5.000 10.00 5.00 Organics, Method 524.2Organics, 524.2 VINYL CHLORIDE, UG/ LVINYL L 1.000 1.00 0.500 1.00 0.100 0.50 0.10 0.050 0.10 0.010 0.05 0.01 0.005 Organics, Method 1625: T= 0Organics, 0 1,2,3 TRICHLOROBENZENE, NG/ UL1,2,3 UL 0.5 5.0 50.0 0.1 0.5 5.0 50.0 0.01 0.10 1.00 10.00 100.00 1.000 Organics, Method 1625: T= 0Organics, 0 1,2 DICHLOROBENZENE, NG/ UL1,2 UL 10.000 1.000 Organics, Method 1625: T= 0Organics, 0 1,2,4 TRICHLOROBENZENE, NG/ UL1,2,4 UL 0.500 0.500 1.000 0.100 0.100 0.050 0.100 0.050 0.010 0.010 0.010 0.005 0.005 0.001 Organics, Method 1625: T= 0Organics, 0 1,2 DIPHENYLHYDRAZINE, NG/ UL1,2 UL 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 5.000 1.000 1.00 0.500 Organics, Method 1625: T= 0Organics, 0 1,3 DICHLOROBENZENE, NG/ UL1,3 UL Organics, Method 1625: T= 0Organics, 0 1,4 DICHLOROBENZENE, NG/ UL1,4 UL 1.000 0.50 0.500 0.100 0.050 0.10 0.100 0.050 0.05 0.010 0.005 0.010 0.01 0.005 Organics, Method 1625: T= 0Organics, 0 2,3,6 TRICHLOROPHENOL, NG/ UL2,3,6 UL 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Mon Mar 18 16: 27: 49 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.01 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 1.00 0.50 0.10 0.05 0.01 0.01 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 0Organics, 0 2,4,5 TRICHLOROPHENOL, NG/ UL2,4,5 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 2,4 DIMETHYLPHENOL, NG/ UL2,4 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 2,6 DINITROTOLUENE, NG/ UL2,6 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 2 NITROPHENOL, NG/ UL2 UL 0.01 0.10 1.00 10.00 100.00 10.000 1.000 0.100 0.010 0.001 0.01 1.00 0.50 0.10 0.05 0.01 0.01 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 0Organics, 0 2,4,6 TRICHLOROPHENOL, NG/ UL2,4,6 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 2,4 DINITROPHENOL, NG/ UL2,4 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 2 CHLORONAPHTHALENE, NG/ UL2 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 2 PICOLINE, NG/ UL2 UL 0.01 0.10 1.00 10.00 100.00 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.01 10.00 1.00 0.10 0.01 0.01 0.500 0.100 0.050 0.010 0.005 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Page 19 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 0Organics, 0 2,4 DICHLOROPHENOL, NG/ UL2,4 UL 0.10 1.00 10.00 100.00 0.10 1.00 10.00 100.00 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 0Organics, 0 2,4 DINITROTOLUENE, NG/ UL2,4 UL Organics, Method 1625: T= 0Organics, 0 2 CHLOROPHENOL, NG/ UL2 UL Organics, Method 1625: T= 0Organics, 0 3,3' DICHLOROBENZIDINE, NG/ UL3,3' UL Log 10 of Observed Standard Deviation Mon Mar 18 16: 28: 03 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 0.10 1.00 10.00 100.00 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 0Organics, 0 4 NITROPHENOL, NG/ UL4 UL 0.01 0.10 1.00 10.00 100.00 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 0Organics, 0 ALPHA TERPINEOL, NG/ ULALPHA UL 0.01 0.10 1.00 10.00 100.00 1.00 0.50 0.10 0.05 0.01 Organics, Method 1625: T= 0Organics, 0 BENZO( A) ANTHRACENE, NG/ ULBENZO( UL 0.05 0.50 5.00 50.00 5.000 Organics, Method 1625: T= 0Organics, 0 4 BROMOPHENYL PHENYL ETHER, NG/ UL4 UL 1.000 0.500 0.100 0.050 0.010 0.005 0.01 10.000 1.000 0.100 0.010 0.001 0.01 1.000 0.100 0.010 0.001 0.01 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 0Organics, 0 4 CHLORO 3 METHYLPHENOL, NG/ UL4 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 ACENAPHTHENE, NG/ ULACENAPHTHENE, UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 ANTHRACENE, NG/ ULANTHRACENE, UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 BENZO( A) PYRENE, NG/ ULBENZO( UL 0.05 0.50 5.00 50.00 1.000 0.500 0.100 0.050 0.010 0.005 Page 20 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 0Organics, 0 4 CHLOROPHENYLPHENYL ETHER, NG/ UL4 UL 0.05 0.50 5.00 50.00 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 0Organics, 0 ACENAPHTHYLENE, NG/ ULACENAPHTHYLENE, UL 0.01 0.10 1.00 10.00 100.00 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 0Organics, 0 BENZIDINE, NG/ ULBENZIDINE, UL 0.01 0.10 1.00 10.00 100.00 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 0Organics, 0 BENZO( B) FLUORANTHENE, NG/ ULBENZO( UL 0.01 0.10 1.00 10.00 100.00 Log 10 of Observed Standard Deviation Mon Mar 18 16: 28: 17 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 1.000 0.500 0.100 0.050 0.010 0.005 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 10.00 Organics, Method 1625: T= 0Organics, 0 BENZO( K) FLUORANTHENE, NG/ ULBENZO( UL 10.00 1.00 1.00 0.10 0.10 0.01 0.01 Page 21 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 0Organics, 0 BETA NAPHTHYLAMINE, NG/ ULBETA UL 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 BIPHENYL, NG/ ULBIPHENYL, UL 5.000 1.0001.000 0.500 0.100 Organics, Method 1625: T= 0Organics, 0 BIS( 2 CHLOROETHOXY) METHANE, NG/ ULBIS( UL 0.100 0.050 0.010 0.010 0.005 0.001 0.001 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 BIS( 2 CHLOROETHYL) ETHER, NG/ ULBIS( UL 1.000 Organics, Method 1625: T= 0Organics, 0 BIS( 2 ETHYLHEXYL) PHTHALATE, NG/ ULBIS( UL 1.000 0.500 0.500 0.100 0.100 0.050 0.050 0.010 0.010 0.005 0.005 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 BIS( 2 CHLOROISOPROPYL) ETHER, NG/ ULBIS( UL Organics, Method 1625: T= 0Organics, 0 BUTYL BENZYL PHTHALATE, NG/ ULBUTYL UL Organics, Method 1625: T= 0Organics, 0 CARBAZOLE, NG/ ULCARBAZOLE, UL 1.000 1.000 0.500 0.100 Organics, Method 1625: T= 0Organics, 0 CHRYSENE, NG/ ULCHRYSENE, UL 0.100 0.050 0.010 0.010 0.005 0.001 Organics, Method 1625: T= 0Organics, 0 DI N BUTYL PHTHALATE, NG/ ULDI UL 0.01 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 0Organics, 0 BENZO( GHI) PERYLENE, NG/ ULBENZO( UL Log 10 of Observed Standard Deviation Mon Mar 18 16: 28: 30 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.00 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.100 0.010 0.001 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.01 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 0Organics, 0 DI N OCTYL PHTHALATE, NG/ ULDI UL 0.50 5.00 50.00 Organics, Method 1625: T= 0Organics, 0 DIBENZOFURAN, NG/ ULDIBENZOFURAN, UL 0.50 5.00 50.00 Organics, Method 1625: T= 0Organics, 0 DIMETHYL PHTHALATE, NG/ ULDIMETHYL UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 FLUORANTHENE, NG/ ULFLUORANTHENE, UL 0.01 0.10 1.00 10.00 100.00 1.00 0.10 0.01 0.01 1.000 0.100 0.010 0.001 0.01 1.000 0.100 0.010 0.001 0.01 10.000 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 0Organics, 0 DI N PROPYLNITROSAMINE, NG/ ULDI UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 DIBENZOTHIOPHENE, NG/ ULDIBENZOTHIOPHENE, UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 DIPHENYL ETHER, NG/ ULDIPHENYL UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 FLUORENE, NG/ ULFLUORENE, UL 0.01 0.10 1.00 10.00 100.00 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.01 10.00 1.00 0.10 0.01 0.01 1.000 0.100 0.010 0.001 Page 22 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 0Organics, 0 DIBENZO( A, H) ANTHRACENE, NG/ ULDIBENZO( UL 0.50 5.00 50.00 Organics, Method 1625: T= 0Organics, 0 DIETHYL PHTHALATE, NG/ ULDIETHYL UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 DIPHENYLAMINE, NG/ ULDIPHENYLAMINE, UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 HEXACHLOROBENZENE, NG/ ULHEXACHLOROBENZENE, UL 0.01 0.10 1.00 10.00 100.00 Log 10 of Observed Standard Deviation Mon Mar 18 16: 28: 44 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 0.500 Organics, Method 1625: T= 0Organics, 0 HEXACHLOROBUTADIENE, NG/ ULHEXACHLOROBUTADIENE, UL 5.000 Organics, Method 1625: T= 0Organics, 0 HEXACHLOROCYCLOPENTADIENE, NG/ ULHEXACHLOROCYCLOPENTADIENE, UL 1.00 1.000 0.500 0.50 0.100 0.050 0.100 0.050 0.10 0.010 0.05 0.010 0.005 0.005 0.05 0.50 5.00 50.00 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 Page 23 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 1625: T= 0Organics, 0 HEXACHLOROETHANE, NG/ ULHEXACHLOROETHANE, UL 10.00 Organics, Method 1625: T= 0Organics, 0 INDENO( 1,2,3 CD) PYRENE, NG/ ULINDENO( UL 1.000 Organics, Method 1625: T= 0Organics, 0 ISOPHORONE, NG/ ULISOPHORONE, UL 10.00 0.500 1.001.00 0.100 0.050 0.10 0.10 0.010 0.005 0.01 0.01 0.001 Organics, Method 1625: T= 0Organics, 0 N DECANE, NG/ ULN UL 0.05 0.50 5.00 50.00 0.05 0.50 5.00 50.00 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 0Organics, 0 N DOCOSANE, NG/ ULN UL 10.000 10.00 1.000 1.000 1.00 0.100 Organics, Method 1625: T= 0Organics, 0 N DODECANE, NG/ ULN UL 0.100 0.10 0.010 0.010 0.01 0.001 0.001 Organics, Method 1625: T= 0Organics, 0 N EICOSANE, NG/ ULN UL 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 10.000 Organics, Method 1625: T= 0Organics, 0 N HEXADECANE, NG/ ULN UL 10.00 10.00 1.000 1.001.00 0.100 0.10 Organics, Method 1625: T= 0Organics, 0 N HEXACOSANE, NG/ ULN UL 0.10 0.010 0.01 0.01 0.001 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 N NITROSODIMETHYLAMINE, NG/ ULN UL Mon Mar 18 16: 28: 58 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.000 Log 10 of Observed Standard Deviation 1.000 Organics, Method 1625: T= 0Organics, 0 N NITROSODIPHENYLAMINE, NG/ ULN UL 10.00 0.500 1.000 1.00 0.100 0.050 Organics, Method 1625: T= 0Organics, 0 N OCTACOSANE, NG/ ULN UL 0.100 0.10 0.010 0.010 0.005 0.01 0.001 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Page 24 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 0Organics, 0 N OCTADECANE, NG/ ULN UL 10.00 10.000 1.000 0.500 Organics, Method 1625: T= 0Organics, 0 N TETRACOSANE, NG/ ULN UL 1.000 Organics, Method 1625: T= 0Organics, 0 N TETRADECANE, NG/ ULN UL 1.00 0.100 0.100 0.10 0.050 Organics, Method 1625: T= 0Organics, 0 N TRIACONTANE, NG/ ULN UL 0.010 0.010 0.01 0.005 0.001 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 10.000 1.000 0.500 Organics, Method 1625: T= 0Organics, 0 NAPHTHALENE, NG/ ULNAPHTHALENE, UL 1.000 1.000 0.500 0.100 0.050 Organics, Method 1625: T= 0Organics, 0 NITROBENZENE, NG/ ULNITROBENZENE, UL 0.100 0.100 0.050 0.010 0.010 0.005 0.010 0.001 0.005 0.001 0.01 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 P CYMENE, NG/ ULP UL 10.00 0.500 1.000 1.00 0.100 Organics, Method 1625: T= 0Organics, 0 PENTACHLOROPHENOL, NG/ ULPENTACHLOROPHENOL, UL 0.100 0.050 Organics, Method 1625: T= 0Organics, 0 PHENANTHRENE, NG/ ULPHENANTHRENE, UL 0.10 0.010 0.010.010 0.001 0.005 Organics, Method 1625: T= 0Organics, 0 PHENOL, NG/ ULPHENOL, UL 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 Mon Mar 18 16: 29: 11 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 1.00 0.50 0.10 0.05 Organics, Method 1625: T= 0Organics, 0 PHENOL, 2 METHYL 4,6 DINITRO, NG/ ULPHENOL, UL 0.01 0.10 1.00 10.00 100.00 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 1,2,3 TRICHLOROBENZENE, NG/ UL1,2,3 UL 10.000 1.000 0.100 0.010 0.001 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 1,2 DIPHENYLHYDRAZINE, NG/ UL1,2 UL 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 2,3,6 TRICHLOROPHENOL, NG/ UL2,3,6 UL Mon Mar 18 16: 29: 25 2002 1.000 0.100 0.010 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 0Organics, 0 PYRENE, NG/ ULPYRENE, UL 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 1,2,4 TRICHLOROBENZENE, NG/ UL1,2,4 UL 0.01 0.10 1.00 10.00 100.00 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 1000Organics, 1000 1,3 DICHLOROBENZENE, NG/ UL1,3 UL 0.05 0.50 5.00 50.00 5.00 1.00 0.50 0.10 0.05 0.01 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 2,4,5 TRICHLOROPHENOL, NG/ UL2,4,5 UL Log 10 of Spike Concentration 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.01 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Page 25 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 0Organics, 0 STYRENE, NG/ ULSTYRENE, UL 0.10 1.00 10.00 100.00 0.50 5.00 50.00 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 c:/ pw/ ostmdl/ req004/ r004sd1. s Organics, Method 1625: T= 1000Organics, 1000 1,2 DICHLOROBENZENE, NG/ UL1,2 UL Organics, Method 1625: T= 1000Organics, 1000 1,4 DICHLOROBENZENE, NG/ UL1,4 UL Organics, Method 1625: T= 1000Organics, 1000 2,4,6 TRICHLOROPHENOL, NG/ UL2,4,6 UL Log 10 of Observed Standard Deviation Episode 6000 Data 1.00 0.50 0.10 0.05 0.01 0.01 1.000 0.100 0.010 0.001 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.001 Organics, Method 1625: T= 1000Organics, 1000 2,4 DICHLOROPHENOL, NG/ UL2,4 UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 2,4 DINITROTOLUENE, NG/ UL2,4 UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 2 CHLOROPHENOL, NG/ UL2 UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 3,3' DICHLOROBENZIDINE, NG/ UL3,3' UL 0.05 0.50 5.00 50.00 1.000 0.500 0.100 0.050 0.010 0.005 0.05 5.000 1.000 0.500 0.100 0.050 0.010 0.005 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.00 0.50 0.10 0.05 0.01 Organics, Method 1625: T= 1000Organics, 1000 2,4 DIMETHYLPHENOL, NG/ UL2,4 UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 2,6 DINITROTOLUENE, NG/ UL2,6 UL 0.1 0.5 5.0 50.0 Organics, Method 1625: T= 1000Organics, 1000 2 NITROPHENOL, NG/ UL2 UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 4 BROMOPHENYL PHENYL ETHER, NG/ UL4 UL 0.01 0.10 1.00 10.00 100.00 1.00 0.50 0.10 0.05 0.05 0.50 5.00 50.00 Page 26 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 1000Organics, 1000 2,4 DINITROPHENOL, NG/ UL2,4 UL 5.00 1.00 0.50 0.10 0.05 0.01 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 2 CHLORONAPHTHALENE, NG/ UL2 UL 5.00 1.00 0.50 0.10 0.05 0.01 Organics, Method 1625: T= 1000Organics, 1000 2 PICOLINE, NG/ UL2 UL 0.5 1.0 5.0 10.0 50.0 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 4 CHLORO 3 METHYLPHENOL, NG/ UL4 UL Log 10 of Observed Standard Deviation Mon Mar 18 16: 29: 39 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s 4 CHLOROPHENYLPHENYL ETHER, NG/ UL4 UL Episode 6000 Data Organics, Method 1625: T= 1000Organics, 1000 0.500 0.100 0.050 0.010 0.005 0.01 0.10 1.00 10.00 100.00 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 1000Organics, 1000 ACENAPHTHYLENE, NG/ ULACENAPHTHYLENE, UL 0.05 0.50 5.00 50.00 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 1000Organics, 1000 BENZIDINE, NG/ ULBENZIDINE, UL 0.05 0.50 5.00 50.00 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 BENZO( B) FLUORANTHENE, NG/ ULBENZO( UL 0.01 0.10 1.00 10.00 100.00 10.00 5.00 Organics, Method 1625: T= 1000Organics, 1000 4 NITROPHENOL, NG/ UL4 UL Page 27 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 1000Organics, 1000 ACENAPHTHENE, NG/ ULACENAPHTHENE, UL 1.000 1.00 0.500 0.50 0.100 0.050 0.10 0.05 0.010 0.005 1 5 10 50 100 0.05 0.50 5.00 50.00 1.000 0.500 Organics, Method 1625: T= 1000Organics, 1000 ALPHA TERPINEOL, NG/ ULALPHA UL 1.000 0.100 0.100 0.050 0.010 0.010 0.005 0.001 0.05 0.50 5.00 50.00 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 ANTHRACENE, NG/ ULANTHRACENE, UL 5.000 1.000 1.000 Organics, Method 1625: T= 1000Organics, 1000 BENZO( A) ANTHRACENE, NG/ ULBENZO( UL 0.500 0.500 0.100 0.100 0.050 0.050 0.010 0.010 0.005 0.005 Organics, Method 1625: T= 1000Organics, 1000 BENZO( A) PYRENE, NG/ ULBENZO( UL 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 10.00 1.000 1.00 0.500 0.100 Organics, Method 1625: T= 1000Organics, 1000 BENZO( GHI) PERYLENE, NG/ ULBENZO( UL 0.10 0.050 0.01 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 BENZO( K) FLUORANTHENE, NG/ ULBENZO( UL 0.01 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 5.000 1.000 Log 10 of Observed Standard Deviation Mon Mar 18 16: 29: 53 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s